Madrigal Pharmaceuticals, Inc.
MDGL
$291.00
$8.142.88%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -73.24M | -59.42M | -106.96M | -151.97M | -147.54M |
| Total Depreciation and Amortization | 435.00K | 363.00K | 298.00K | 267.00K | 168.00K |
| Total Amortization of Deferred Charges | 436.00K | 482.00K | 480.00K | 472.00K | 655.00K |
| Total Other Non-Cash Items | 20.93M | 17.73M | 17.44M | 24.40M | 19.90M |
| Change in Net Operating Assets | -37.46M | -63.65M | 21.76M | -8.12M | -22.34M |
| Cash from Operations | -88.89M | -104.49M | -66.98M | -134.95M | -149.16M |
| Capital Expenditure | -- | -195.00K | -779.00K | -131.00K | -357.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 163.88M | -47.76M | -201.61M | -121.97M | 98.41M |
| Cash from Investing | 163.88M | -47.95M | -202.39M | -122.10M | 98.05M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8.64M | 19.77M | 7.46M | 134.12M | 573.71M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 8.64M | 19.77M | 7.46M | 134.12M | 573.71M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.63M | -132.67M | -261.91M | -122.92M | 522.60M |